JPS625132B2 - - Google Patents
Info
- Publication number
- JPS625132B2 JPS625132B2 JP10700878A JP10700878A JPS625132B2 JP S625132 B2 JPS625132 B2 JP S625132B2 JP 10700878 A JP10700878 A JP 10700878A JP 10700878 A JP10700878 A JP 10700878A JP S625132 B2 JPS625132 B2 JP S625132B2
- Authority
- JP
- Japan
- Prior art keywords
- strain
- virus
- cells
- vaccinia virus
- attenuated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000004027 cell Anatomy 0.000 claims description 69
- 241000700605 Viruses Species 0.000 claims description 61
- 241000700618 Vaccinia virus Species 0.000 claims description 60
- 241000287828 Gallus gallus Species 0.000 claims description 36
- 230000002238 attenuated effect Effects 0.000 claims description 34
- 239000002356 single layer Substances 0.000 claims description 22
- 230000001605 fetal effect Effects 0.000 claims description 21
- 230000005965 immune activity Effects 0.000 claims description 19
- 210000003292 kidney cell Anatomy 0.000 claims description 15
- 239000010410 layer Substances 0.000 claims description 15
- 241000283977 Oryctolagus Species 0.000 claims description 13
- 229960001438 immunostimulant agent Drugs 0.000 claims description 11
- 230000001404 mediated effect Effects 0.000 claims description 11
- 239000003022 immunostimulating agent Substances 0.000 claims description 8
- 230000003308 immunostimulating effect Effects 0.000 claims description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000001018 virulence Effects 0.000 claims description 6
- 238000007796 conventional method Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 38
- 235000013330 chicken meat Nutrition 0.000 description 32
- 238000012360 testing method Methods 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 19
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000011550 stock solution Substances 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 210000003754 fetus Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 241001494479 Pecora Species 0.000 description 10
- 208000037062 Polyps Diseases 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 5
- 208000006268 Sarcoma 180 Diseases 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 241000700647 Variola virus Species 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 206010024769 Local reaction Diseases 0.000 description 3
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000003855 balanced salt solution Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- -1 etc. as necessary Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 239000002584 immunological anticancer agent Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SKDFWEPBABSFMG-UHFFFAOYSA-N 1,2-dichloro-1,1-difluoroethane Chemical compound FC(F)(Cl)CCl SKDFWEPBABSFMG-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 230000005156 neurotropism Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10700878A JPS5535004A (en) | 1978-09-02 | 1978-09-02 | Cell-immunity activator and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10700878A JPS5535004A (en) | 1978-09-02 | 1978-09-02 | Cell-immunity activator and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5535004A JPS5535004A (en) | 1980-03-11 |
| JPS625132B2 true JPS625132B2 (enrdf_load_stackoverflow) | 1987-02-03 |
Family
ID=14448150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10700878A Granted JPS5535004A (en) | 1978-09-02 | 1978-09-02 | Cell-immunity activator and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5535004A (enrdf_load_stackoverflow) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5869104A (ja) * | 1982-05-29 | 1983-04-25 | Nec Corp | Ｆｍ変調器の並列運転方式 |
| JPS6038328A (ja) * | 1983-08-11 | 1985-02-27 | Handai Biseibutsubiyou Kenkyukai | 抗腫瘍免疫誘導の増強法 |
| BRPI0411526A (pt) | 2003-06-18 | 2006-08-01 | Genelux Corp | vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos |
| EP2097517B1 (en) | 2006-10-16 | 2014-06-04 | Genelux Corporation | Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody |
-
1978
- 1978-09-02 JP JP10700878A patent/JPS5535004A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5535004A (en) | 1980-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Duff | The oral immunization of trout against Bacterium salmonicida | |
| EP0020356B1 (en) | Pasteurellosis vaccines | |
| US3985615A (en) | Process for preparing live varicella vaccines | |
| US3869547A (en) | Calf diarrhea virus vaccine and processes | |
| Lemonde et al. | Influence of Bacille Calmette-Guérin infection on polyoma in hamsters and mice | |
| US4315914A (en) | Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof | |
| US4191745A (en) | Preparation for the treatment of Herpes zoster and other Herpes infections, as well as method for manufacture thereof | |
| PL145565B1 (en) | Method of obtaining a vaccine for therapeutically and prophylactically treating infections of respiratory tracts of humans | |
| JPH06505730A (ja) | ヒトにおいてエンテロトキシン産生大腸菌により起こる腸感染症／下痢に対して接種するためのホルマリン殺菌したコロニー形成因子抗原（ｃｆａ）−発現性大腸菌の調製および使用 | |
| CA1039187A (en) | Feline leukemia vaccines | |
| Abodalal et al. | Development and production of a novel bivalent inactivated rabbit haemorrhagic disease virus (RHDV) vaccine. | |
| Mel et al. | Studies on vaccination against bacillary dysentery: 1. Immunization of mice against experimental Shigella infection | |
| DK163067B (da) | Biologisk ren praeparation af en smitsom bronkitis-virusstamme | |
| AU705186B2 (en) | Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection | |
| EP0037441B1 (en) | Pharmaceutical compositions useful as cellular immunopotentiator and anti-tumor agent, process for production thereof and microorganism used therein | |
| JPS625132B2 (enrdf_load_stackoverflow) | ||
| JP3522772B2 (ja) | ワクチンの免疫効果増強剤 | |
| KR102656435B1 (ko) | 신규한 가금 아데노바이러스 및 이를 유효성분으로 포함하는 가금 아데노바이러스 다가백신 | |
| Fairbrother et al. | Active Immunization against Experimental Influenza: The Use of Heat-killed Elementary Body Suspensions | |
| IE45145B1 (en) | Immunostimulating agent | |
| US4837018A (en) | Vaccines for fowl colibacillosis | |
| HU210344A9 (en) | Cell free mareks disease virus vaccine | |
| Torrey et al. | The treatment of Flexner-Jobling rat carcinomas with bacterial proteolytic ferments | |
| JPS5817169B2 (ja) | シンセイコウシゲリワクチンノ セイホウ | |
| HU206050B (en) | Process for producing hantaan virus vaccine |